tradingkey.logo
tradingkey.logo
Search

AC Immune SA

ACIU
Add to Watchlist
2.510USD
+0.130+5.46%
Close 07/02, 13:00ETQuotes delayed by 15 min
255.45MMarket Cap
LossP/E TTM

TradingKey Stock Score of AC Immune SA

Currency: USD Updated: 2026-07-02

Key Insights

AC Immune SA's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 118 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 8.60.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

AC Immune SA's Score

Industry at a Glance

Industry Ranking
118 / 387
Overall Ranking
242 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive+

AC Immune SA Highlights

StrengthsRisks
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.52M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.52M.
Overvalued
The company’s latest PE is -3.04, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 26.78M shares, decreasing 5.96% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 389.08 shares of this stock.

Analyst Rating

Based on 4 analysts
Strong Buy
Current Rating
8.600
Target Price
+261.34%
Upside Space

FAQs

How does TradingKey generate the Stock Score of AC Immune SA?

The TradingKey Stock Score provides a comprehensive assessment of AC Immune SA based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of AC Immune SA’s performance and outlook.

How do we generate the financial health score of AC Immune SA?

To generate the financial health score of AC Immune SA, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects AC Immune SA's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of AC Immune SA.

How do we generate the company valuation score of AC Immune SA?

To generate the company valuation score of AC Immune SA, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare AC Immune SA’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of AC Immune SA’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of AC Immune SA.

How do we generate the earnings forecast score of AC Immune SA?

To calculate the earnings forecast score of AC Immune SA, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on AC Immune SA’s future.

How do we generate the price momentum score of AC Immune SA?

When generating the price momentum score for AC Immune SA, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of AC Immune SA’s prices. A higher score indicates a more stable short-term price trend for AC Immune SA.

How do we generate the institutional confidence score of AC Immune SA?

To generate the institutional confidence score of AC Immune SA, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about AC Immune SA’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of AC Immune SA.

How do we generate the risk management score of AC Immune SA?

To assess the risk management score of AC Immune SA, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of AC Immune SA’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of AC Immune SA.